4D몰큘러 테라퓨틱스 (FDMT)

Dec 21, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Dec 21, 2024

Dec 18, 2024

What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics - Benzinga

Dec 18, 2024

Dec 18, 2024

Bank of America Has Lowered Expectations for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price - MarketBeat

Dec 18, 2024

Dec 17, 2024

Short Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Increases By 8.8% - MarketBeat

Dec 17, 2024

Dec 16, 2024

4D Molecular Therapeutics' SWOT analysis: gene therapy stock faces pivotal year - Investing.com India

Dec 16, 2024

Dec 16, 2024

4DMT Announces Landmark Publication of 4D-150 Preclinical - GlobeNewswire

Dec 16, 2024

Dec 16, 2024

4D Molecular's R100 Vector Shows 10X Potency Breakthrough in Landmark Eye Disease Study - StockTitan

Dec 16, 2024

Dec 13, 2024

4D Molecular Therapeutics stock hits 52-week low at $6.69 By Investing.com - Investing.com Canada

Dec 13, 2024

Dec 12, 2024

4D Molecular Therapeutics issues pre-funded warrant to RA Capital - Investing.com

Dec 12, 2024

Dec 12, 2024

4D Molecular Therapeutics issues pre-funded warrant to RA Capital By Investing.com - Investing.com Canada

Dec 12, 2024

Dec 07, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 07, 2024

Dec 07, 2024

84,322 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Acquired by Walleye Capital LLC - MarketBeat

Dec 07, 2024

Dec 06, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - The Eastern Progress Online

Dec 06, 2024

Dec 06, 2024

BlackRock, Inc. Expands Stake in 4D Molecular Therapeutics Inc - GuruFocus.com

Dec 06, 2024

Dec 05, 2024

4D Molecular Therapeutics' SWOT analysis: gene therapy stock faces pivotal phase - Investing.com India

Dec 05, 2024

Dec 05, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Purchased by Redmile Group LLC - MarketBeat

Dec 05, 2024

Dec 04, 2024

4D Molecular Therapeutics stock hits 52-week low at $7.32 By Investing.com - Investing.com South Africa

Dec 04, 2024

Dec 03, 2024

4D Molecular Therapeutics stock hits 52-week low at $7.32 - Investing.com India

Dec 03, 2024

Nov 30, 2024

Healthcare of Ontario Pension Plan Trust Fund Sells 247,000 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat

Nov 30, 2024

Nov 30, 2024

Braidwell LP Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat

Nov 30, 2024

Nov 26, 2024

4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now - Insider Monkey

Nov 26, 2024

Nov 25, 2024

4D Molecular Therapeutics (NASDAQ:FDMT) Now Covered by Morgan Stanley - Defense World

Nov 25, 2024

Nov 24, 2024

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth - Simply Wall St

Nov 24, 2024

Nov 21, 2024

Morgan Stanley sees competitive challenges ahead for 4D Molecular stock By Investing.com - Investing.com Canada

Nov 21, 2024

Nov 21, 2024

4D Molecular initiated by Morgan Stanley at underweight - MSN

Nov 21, 2024

Nov 18, 2024

FY2024 Earnings Forecast for FDMT Issued By Leerink Partnrs - MarketBeat

Nov 18, 2024

Nov 18, 2024

HC Wainwright Has Negative Outlook for FDMT FY2024 Earnings - MarketBeat

Nov 18, 2024

Nov 15, 2024

4D Molecular Therapeutics’ Positive Q3 and Strategic Advances - TipRanks

Nov 15, 2024

Nov 15, 2024

RA Capital Management, L.P. Increases Stake in 4D Molecular Ther - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Janus Henderson Group PLC's Strategic Adjustment in 4D Molecular Therapeutics Inc Holdings - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Analyst Expectations For 4D Molecular Therapeutics's Future - Benzinga

Nov 14, 2024

Nov 14, 2024

Deep Track Capital, LP Increases Stake in 4D Molecular Therapeutics Inc - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

4D Molecular Sets Major Conference Schedule: Jefferies, Evercore & OIS XIV Appearances | FDMT Stock News - StockTitan

Nov 14, 2024

Nov 14, 2024

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 14, 2024

Nov 13, 2024

4D Molecular Therapeutics Inc Reports Q3 2024 EPS of $(0.79) and Revenue of $3,000 - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times

Nov 13, 2024

Nov 13, 2024

4D Molecular Reports Positive AMD Trial Data, $551M Cash Position Funds Operations to 2027 | FDMT Stock News - StockTitan

Nov 13, 2024

Nov 13, 2024

4D Molecular Therapeutics stock hits 52-week low at $7.9 By Investing.com - Investing.com Australia

Nov 13, 2024

Nov 12, 2024

4D Molecular Therapeutics stock hits 52-week low at $7.9 - Investing.com India

Nov 12, 2024

Nov 12, 2024

4D Molecular Therapeutics Inc. (FDMT) Quarterly 10-Q Report - Quartz

Nov 12, 2024

Nov 12, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $47.14 Consensus PT from Analysts - MarketBeat

Nov 12, 2024

Nov 12, 2024

BioSpace Announces 2025 Best Places to Work in Biopharma - BioSpace

Nov 12, 2024

Nov 07, 2024

X-Linked Retinitis Pigmentosa Clinical Trials 2024: FDA - openPR

Nov 07, 2024

Nov 07, 2024

Goldman Sachs Group Inc's Strategic Reduction in 4D Molecular Th - GuruFocus.com

Nov 07, 2024

Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition of Shares in 4D Molec - GuruFocus.com

Nov 05, 2024